Zusammenfassung
Unter dem Begriff Diabetes mellitus wird eine Gruppe von Stoffwechselstörungen zusammengefasst, deren gemeinsames Merkmal eine pathologische Erhöhung der Blutglukose ist. Quantitativ wird für die Diagnose eines Diabetes eine nüchtern bestimmte Plasmaglukose ≥ 126 mg/dl, eine postprandiale Plasmaglukose ≥ 200 mg/dl in Verbindung mit Symptomen der Hyperglykämie (wie vermehrter Harnausscheidung, Durst, Müdigkeit) oder eine Plasmaglukose von ≥ 200 mg/dl zwei Stunden nach der Gabe von 75 g Glukose im oralen Glukosetoleranztest gefordert (American Diabetes Association, 2005).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literaturverzeichnis
Adult Treatment Panel III (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2497
American Diabetes Association (2004) Gestational diabetes mellitus. Diabetes Care 27Suppl 1: S88–S90
American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28Suppl 1: S37–S42
American Diabetes Association (2008) Standards of medical care in diabetes-2008. Diabetes Care 31Suppl 1: S12–S54
Drexel H, Saely CH, Langer P, Loruenser G, Marte T, Risch L, Hoefle G, Aczel S (2008) Metabolic and anti-inflammatory benefits of eccentric endurance exercise-a pilot study. Eur J Clin Invest 38: 218–226
Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S (2003) A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348: 2082–2090
Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M (2002) Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25: 148–198
Fried SK, Rao SP (2003) Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 78: 873S–880S
Gardner CD, Kiazand A, Alhassan S, Kim S, Stafford RS, Balise RR, Kraemer HC, King AC (2007) Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297: 969–977
Garg A, Bantle JP, Henry RR, Coulston AM, Griver KA, Raatz SK, Brinkley L, Chen YD, Grundy SM, Huet BA (1994) Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 271: 1421–1428
Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
Hoefle G, Saely CH, Aczel S, Benzer W, Marte T, Langer P, Drexel H (2005) Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. Int J Obes (Lond) 29: 785–791
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154–e235
Kendall CW, Jenkins DJ (2004) A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet. Curr Atheroscler Rep 6: 492–498
Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG (2004) Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 27: 2067–2073
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403
Moreno JJ, Mitjavila MT (2003) The degree of unsaturation of dietary fatty acids and the development of atherosclerosis (review): J Nutr Biochem 14: 182–195
Muller WA (1998) Diabetes mellitus-long time survival. J Insur Med 30: 17–27
Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Jr., Brehm BJ, Bucher HC (2006) Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 166: 285–293
Oomen CM, Ocke MC, Feskens EJ, Erp-Baart MA, Kok FJ, Kromhout D (2001) Association between trans fatty acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-based study. Lancet 357: 746–751
Österreischische Diabetes Gesellschaft (2007) Diabetes mellitus-guidelines for general practice. Revised and expande 2007 edition. Wien Klin Wochenschr 119: 5–64
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
Pittler MH, Stevinson C, Ernst E (2003) Chromium picolinate for reducing body weight: meta-analysis of randomized trials. Int J Obes Relat Metab Disord 27: 522–529
Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ (2003) Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 24: 610–628
Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H (2005) The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90: 5698–5703
Saely CH, Rein P, Drexel H (2007) The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm Metab Res 39: 642–650
Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752
Stern L, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams M, Gracely EJ, Samaha FF (2004) The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 140: 778–785
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350
West SG, Hecker KD, Mustad VA, Nicholson S, Schoemer SL, Wagner P, Hinderliter AL, Ulbrecht J, Ruey P, Kris-Etherton PM (2005) Acute effects of monounsaturated fatty acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. Diabetologia 48: 113–122
Literaturverzeichnis
Aslander-Van Vliet E, Smart C, Waldron S (2007) Nutritional management in childhood and adolescent diabetes. ISPAD Clinical Practise Concensus Guidelines 2006–2007. Pediatric Diabetes 8(5): 323–339
Diabetes and Nutrition Study Group (DNSG) of the EASD (2004) Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 15: 373–394
Donaghue K, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K (2007) Microvascular and macrovascular Compliactions. Pediatric Diabetes 8(3): 163–170
Kawamura T (2007) The importance of carbohydrate counting in the treatment of children with diabetes. Pediatric Diabetes 8(Suppl 6): 57–62
Kerner W, Brückel J, Böhm BO (2004) Definition, Klassifikation und Diagnostik des Diabetes mellitus. Evidenzbasierte Leitlinie Deutsche Diabetes Gesellschaft-http://www.deutsche-diabetes-gesellschaft.de
Knerr I, Hofer S, Holterhus P, Naeke A, Rosenbauer J, Weitzel D, Wolf J, Holl RW (2007) Prevailing therapeutic regimens and predictive factors for prandial insulin substitution in 26.687 children and adolescents with type 1 diabetes in Germany and Austria. Diabetic medicine 24(12): 1478–1481
Kruse J, Petrak F, Herpertz S, Albus C, Lange K, Kulzer B. (2006) Diabetes and depression-a life-endangering interaction. Z Psychosom Med Psychother 52(3): 289–309
Lagarde W, Barrows F, Davenport M, Kang M, Guess H, Calikoglu A (2006) Continuous subcutaneous glucose monitoring in children with type 1 diabetes mellitus: a single-blind, randomised controlled trial. Pediatric Diabetes 7(3): 159–164
Meisinger B, Hofer A, Jörg-Streller M, Grissenauer G (2006) Ernährungstabellen für Kinder und Jugendliche. Zeichnung Frau Veronika Jud.
Rami B, Schober E, Nachbauer E, Waldhör T (2003) Typ 2 Diabetes mellitus is rare but not absent in children under 15 years of age in Austria. European Journal of Pediatrics 162(12): 850–852
Rami B, Prchla Ch, Arocker W, Bittmann B, Mühleder H, Jäger A, Hofer S, Fröhlich-Reiterer E, Schober E für die APED-Gruppe (2007) Diabetes im Kindes-und Jugendalter. Wien Klin Wochenschr 119(Suppl 2): 54–57
Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingenscmith GJ (2007) Assessment and monitoring of glycemic contol in children and adolescents with diabetes. Pediatric Diabetes 8: 408–418
Schiffrin A, Belmonte M (1982) Multiple daily self-glucose control in insulin. dependent diabetic patients treated with pump and multiple subcutaneus injections. Diabetes Care 5: 479–484
Vanelli M (2008) Available tools for primary ketoacidosis prevention at diabetes diagnosis in children and adolescents. „The Parma Campaign“. Acta BioMedica 79: 1–8
Literaturverzeichnis
Banarer S, Cryer PE (2003) Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 52: 1195–1203
Czerwenka-Howorka K, Bratusch-Marrain P, Waldhäusl W (1984) Algorithmen der normoglykämischen Insulinsubstitution bei Typ 1-Diabetes. Erste Langzeiter-Langzeitergebnisse. Wien Klin Wochenschr 14: 458–459
Howorka K (1988) Funktionelle, nahe-normoglykämische Insulinsubstitution. Springer, Berlin Heidelberg New York London Paris Tokio
Irsigler K, Bali-Taubald C (1980) Self-monitored blood glucose: The essential biofeedback signal in the diabetic patient’s effort to achieve normoglycemia. Diabetes Care 3: 163
Kadish AH (1963) Automation control of blood sugar. A servomechanism for glucose monitoring and control. Trans Am Soc Artif Intern Organs 9: 363
Kritz H, Koller W, Regal H, Taubald C, Irsigler K (1979) Blutzuckerselbstabnahme — Verbesserung der Diabeteseinstellung durch ambulante Tagesprofile. Medizinische Klinik 76: 267ff
Pickup JC, Keen H, Parsons JA, Alberti KGMM (1977) The use of continuous subcutaneous insulin infusion to achieve normoglycemia in diabetic patients. Diabetologia 13: 425ff
Schiffrin A, Belmonte M (1982) Multiple daily self glucose monitoring: Its essential role in longterm glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care 5: 479–484
Skyler JS, Skyler DL, Seigler DE, O Sullivan MJ (1981) Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. Diabetes Care 4: 311–318
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986
Literaturverzeichnis
Backes JM, Gibson CA, Howard PA (2005) Optimal lipid modification: the rational for combination therapy. Vasc Health Risk Manag 1: 317–331
Bamberger MJ, Lane MD (1988) Assembly of very low density lipoprotein in the hepatocyte: differential transport of apoproteins through the secretory pathway. J Biol Chem 263: 11868–11878
Breslow JL (1993) Genetics of lipoprotein disorders. Circulation 8: S16–S21
Briggs MR, Yokayama C, Wang X, Brown MS, Goldstein JL (1993) Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor protein. J Biol Chem 268: 1490–1496
Brown MS, Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331–340
Cheng AY, Leiter AY (2006) Implications of recent clinical trials for the National Cholesterol Education Program Adults III guidelines. Curr Opin Cardiol 21: 400–404
Cholesterol Treatment Trialists (CTT) collaborators (2005) Efficacy and safety of cholesterol-lowering treatemtnt: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278
Expert panel on detection and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285: 544–560
Foeger B, Patsch JR (1995) Exercise and postprandial lipaemia. J Cardiovasc Risk 2: 316–322
Friedewald WT, Levy RI, Fredrickson DS (1972) Estima-Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502
Gille A, Bodor ET, Ahmed K, Offerman S (2008) Nicotinic acid: pharmacological effects and mechanism of action. Annu Rev Pharmacol Toxicol 48: 79–106
Goldberg IJ (2000) Diabetic dyslipidemia: causes and consequnces. J Clin Endocrin Metab 86: 965–971
Goldstein JL, Hopps HH, Brown MS (1995) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. Mc Graw-Hill, New York, pp 1981–2030
Gould LA, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1998) Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97: 946–952
Hu FB, Manson JE, Willett WC (2001) Types of dietary fat and risk of coronary heart diseas: a critical review. J Am Coll Mutr 20: 5–19
Jones PH, Davodson MH (2005) Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 95: 120–122
Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterila wall? Nat Clin Pract Cardiovasc Med 3: 144–153
Kostner GM, Krempler F (1992) Lipoprotein (a). Curr Opin Lipidol 3: 279–284
Kronenberg F, Uterman G, Dieplinger H (1996) Lipoprotein (a) in renal disease. Am J Kidney Dis 27: 1–25
La Rosa JC, Hunnunghake D, Bush D et al. (1990) The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 81: 1721–1733
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchard JC, Ghotto AM, Greten H, Kastelein JJ, Sheperd J, Wenger NK (2005) Treating to new targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435
LaRosa JC, He J, Vupputuri S (1999) Effect of statins on risk of coronary disease: a meta-analyis of randomized controlled trials. JAMA 282: 2340–2346
Lee JH, O’Keefe JH, Lavie CJ, Marchioli R, Harris WS (2008) Omega3fatty acids for cardioprotection. Mayo Clin Proc 83: 324–332
Lewis GF (2006) Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol 2: 345–352
McKeone BJ, Patsch JR, Pownall HJ (1993) Plasma triglycerides determine low density lipoprotein composition, physical properties, and cell-specific binding in cultures cells, J Clin Invest 91: 1926–1033
Miller NE (1987) Association of high-density lipoprotein subclass and apolipoprotein with ischemic heart disease and coronary arterosclerosis. Am Heart J 113: 589–597
Noakes M, Clifton PM (2000) Changes in plasma lipids and other cardiovascular risk factors during 3 energy-restricted diets differing in total fat and fatty acid composition. Am J Clin Nutr 71: 706–712
Österreichische Atherosklerosegesellschaft (2006) AAS Cholesterin-Konsensus 2006 (http://www. aas. at)
Packard CJ, Sheperd J (1999) Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism. In: Betteridge DJ et al. (eds) Lipoproteins in Health and Disease. Arnold, London, pp 17–30
Pasternak RC, Smith SC jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002) American College of Cardiology; American heart Association, National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567–572
Patsch JR (1994) Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis 110: S23–26
Patsch JR, Prasad S, Gott Amjr, Patsch W (1987) High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of the lipoprotein lipase and hepatic lipase. J Clin Invest 80: 341–347
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J — Incremental increase in end points through aggressive lipid lowering (IDEAL) study group (2005) High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437–2445
Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S (2005) Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA-reductase inhibitor therapy. Drg Saf 28: 263–275
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J (1999) Gemfibrozil for the prevention of coronary heart disease in men with low high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study group. N Engl J Med 341: 410–418
Rudkowska I, Jones PJ (2007) Functional foods for the prevention and treatment of cardiovascular diseases: cholesterol and beyond. Expert Rev Cardiovasc Ther 5: 477–490
Sheperd J (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism 9: 609–616
Steiner G (2007) Atherosclerosis in type 2 diabetes: a role for fibrate therapy? Diabet Vasc Dis Res 4: 368–374
Stocker R, Keaney JF jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381–1370
Yatskar L, Fisher EA, Schwartzbard A (2006) Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin Cardiol 29: 52–55
Literatur
Allen LH (2008) Causes of vitamin B12 and folate deficiency. Food Nutr Bull 29: S20–S34
Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR (2000) Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 102: 1227–1232
Beitz R, Mensink GB, Fischer B, Thamm M (2002) Vitamins-dietary intake and intake from dietary supplements in Germany. Eur J Clin Nutr 56: 539–545
Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH (1999) Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol 19: 2241–2244
Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D’Agostino RB, Wolf PA, Jacques PF, Wilson PW (1999) Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 159: 1077–1080
Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 274: 1049–1057
Chen P, Poddar R, Tipa EV, Dibello PM, Moravec CD, Robinson K, Green R, Kruger WD, Garrow TA, Jacobsen DW (1999) Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul 39: 93–109
Chiang PK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McKann PP (1996) S-adenosylmethionine and methylation. FASEB J 10: 471–480
Christensen B, Refsum H, Vintermayr O, Ueland PM (1991) Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: methionine loading of nontransformed, transformed, proliferating, and quiescent cells in culture. J Cell Physiol 146: 52–62
Clarke R (B-Vitamin Treatment trialists’ Collaboration) (2006) Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 151: 282–287
Clarke R, Armitage J (2000) Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Sem Thromb Hemost 26: 341–348
De Bree A, van Dusseldorp M, Brouwer IA, van het Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 51: 643–660
Donnelly JG (2001) Folic Acid. Crit Rev Clin Lab Sci 38: 183–223
Du Vigneaud VE (1952) A Trail of Research in Sulfur Chemistry and Metabolism, and Related Fields Cornell University Press, Ithaca-New York
Dudman NP, Guo XW, Gordon RB, Dawson PA, Wilcken DE (1996) Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease. J Nutr 126: S1295–S300
Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D (2001) Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 81: 645–672
Finkelstein JD (2000) Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost 26: 219–225
Gerritsen T, Vaughn JG, Waisman HA (1962) The identification of homocystine in the urine. Biochem Biophys Res Commun 9: 493–496
Gibson JB, Carson NA, Neill DW (1964) Pathological findings in homocystinuria. J Clin Pathol 17: 427–437
Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH (1997) Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 277: 1775–1781
Guttormsen AB, Schneede J, Ueland PM, Refsum H (1996) Kinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am J Clin Nutr 63: 194–202
Guttormsen AB, Ueland PM, Svarstad E, Refsum H (1997) Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52: 495–502
Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58: 295–300
Jacob RA, Wu MM, Henning SM, Swendseid ME (1994) Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 124: 1072–1080
Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 7–9
Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, Rosendaal FR (2002) Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 88: 723–728
Kraus JP, Janosík M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LA, Blom H, Boers GH, Gordon RB, Kamoun P, Tsai MY, Kruger WD, Koch HG, Ohura T, Gaustadnes M (1999) Cystathionine beta-synthase mutations in homocystinuria. Hum Mutat 13: 362–375
Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 699–707
Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG (1989) Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int 36: S73–S80
Levy HL, Mudd SH, Schulman JD, Dreyfus PM, Abeles RH (1970) A derangement in B12 metabolism leading to homocystinemia, cystathioninemia, hypomethioninemia and methylmalonic aciduria. Am J Med 48: 390–397
Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J (2006) The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567–1577
McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111–128
Morrow G, Barness LA (1972) Combined vitamin responsiveness in homocystinuria. J Pediatr 81: 946–954
Mudd SH, Finkelstein JD, Irreverre F, Laster L (1964) Homocystinuria: an enzymatic defect. Science 143: 1443–1445
Mudd SH, Levy HL, Abeles RH, Jennedy JP (1969) A derangement in B 12 metabolism leading to homocystinemia, cystathioninemia and methylmalonic aciduria. Biochem Biophys Res Comm 35: 121–126
Mudd SH, Poole JR (1975) Labile Methyl balances for normal humans on various dietary regimens. Metabolism 24:721–735
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R (1985) The natural history of homocystinuria due to cystathionine-beta-synthase deficiency. Am J Hum Genet 37:1–31
Mudd SH, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih JE (1972) Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 46: 905–912
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE (1997) Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337: 230–236
Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38: 1933–1953
Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ (1997) Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95: 1777–1782
Rose WC, Haines WJ, Warner DT, Johnson JE (1950) The amino acid requirements of man. 1. The role of valine and methionine. J Biol Chem 182: 541–555
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990 s. Nature 362: 801–809
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 270: 2693–2698
Selhub J, Miller JW (1992) The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylhomocysteine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55: 131–138
Spence JD, Bang H, Chambless LE, Stampfer MJ (2005) Vitamin intervention for stroke prevention trial. An efficacy analysis. Stroke 36: 2404–2409
Stanger O (2004) Homocystein: Grundlagen, Klinik, Therapie, Prävention. Verlag Wilhelm Maudrich, Wien
Stanger O (2008) http://www.dach-liga-homocystein.org/Fachlit/kommentare/komment/01komm.pdf [19. 12. 2008]
Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M (2003) Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Clin Chem Lab Med 41: 1392–1403
Stanger O, Weger M, Renner W, Konetschny R (2001) Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 39: 725–733
Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ (1996) The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 98: 177–184
Ueland PM, Clarke R (2007) Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power. Clin Chem 53: 807–809
Van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD (1998) No net renal extraction of homocysteine in fasting humans. Kidney Int 54: 166–169
Van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, Donker AJ, Stehouwer CD, De Meer K (1999) Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 56: 1064–1071
Wald DS, Law M, Morris JK (2002) Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202–1208
Wang H, Yoshizumi M, Lai K, Tsai JC, Perrella MA, Haber E, Lee ME (1997) Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 272: 25380–25385
Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369: 1876–1882
Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, Thomson A, Ueland PM, Ebrahim SB (1999) Serum total plasma homocysteine and coronary heart disease: prospective study in middle-aged men. Heart 82: 448–454
Wilcken DE, Wilcken B (1976) The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57: 1079–1082
Wilcken DE, Wilcken B (1997) The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20: 295–300
Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA (1983) Homocystinuria-the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 309: 448–453
Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM (2006) Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 13: 1335–1343
Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER (2001) Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically. A multicenter observational study. Arterioscler Thromb Vasc Biol 21: 2080–2085
Yap S, Naughten E (1998) Homocystinuria due to cystathionine beta-synthase deficiency in Ireland: 25 years’ experience of a newborn screened and treated population with reference to clinical outcome and biochemical control. J Inherit Metab Dis 21: 738–747
Literaturverzeichnis
Apeland T, Mansoor MA, Pentieva K, McNulty H, Seljeflot I, Strandjord RE (2002) The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res 51: 237–247
Bässler KH (1988) Megavitamin therapy with pyridoxine. Int J Vit Nutr Res 58: 105–118
Baumgartner-Sigl S, Haberlandt E, Mumm S, Scholl-Bürgi S, Sergi C, Ryan L, Ericson KL, Whyte MP, Högler W (2007) Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p. M226T; c.1112C>T, p. T371I) of the tissue-nonspecific alkaline phosphatase gene. Bone 40:1655–1661
Baxter P (2001) Pyridoxine dependent/responsive seizures. In: Baxter P (ed) Vitamin Responsive Conditions in Paediatric Neurology. MacKeith Press, London, pp 109–165
Bender DA (1987) Oestrogens and vitamin B6-actions and interactions. World Rev Nutr Diet 51: 140–188
Bender DA (1989) Vitamin B6 requirements and recommendations. Eur J Clin Nutr 43: 289–309
Bender DA (1994) Novel Functions of Vitamin B6. Proc Nutr Soc 53: 625–630
Bender DA, Wynick D (1981) Inhibition of kynureninase (L-kynurenine hydrolase, EC 3.7.1.3) by oestrone sulphate, an alternative explanation for abnormal results of tryptophan load test in women receiving oestrogenic steroids. Br J Nutr 45: 269–275
Bender DA (1999) Non-nutritinal uses of vitamin B6. Br J Nutr 81: 7–20
Bendich A, Cohen M (1990) Vitamin B6 safety issues. Ann N Y Acad Sci 585: 321–330
Booth AA, Khalifah RG, Hudson BG (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 220: 113–119
Bor MV, Refsum H, Bisp MR, Bleie O, Schneede J, Nordehaug JE, Ueland PM, Nygard O, Nexo E (2003) Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study. Clin Chem 49: 155–161
Bowe CM, Veale K (1988) Sensitivity to 4-aminopyridine observed in mammalian sciatic nerves during acute pyridoxine-induced sensory neuropathy and recovery. Exp Neurol 100: 448–458
Brants HA, Brussaard JH, Bouman M, Löwik MR (1997) Dietary intake among adults with special reference to vitamin B6. Eur J Clin Nutr 51: S25–S31
Canham JE, Baker EM, Harding RS, Sauberlich HE, Plough IC (1969) Dietary protein-its relationship to vitamin B6 requirements and function. Ann N Y Acad Sci 166: 16–29
Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM (2001) Low Plasma Levels of Vitamin B6 are Independently Associated With a Heightened Risk of Deep-vein Thrombosis. Circulation 104: 2442–2446
Chang SJ, Chuang HJ, Chen HH (1999) Vitamin B6 down-regulates the expression of human GPIIb gene. J Nutr Sci Vitaminol 45: 471–479
Chetyrkin S, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA (2005) Pyridoxamine lowers kidney chrystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int 67: 53–60
Cidlowski JA, Thanasi JW (1981) Pyridoxal phosphate, a possible cofactor role in steroid hormone action. J Steroid Biochem 15: 11–16
Clayton PT (2006) B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis 29: 317–326
Coburn SP, Lewis DL, Fink WJ, Mahuren JD, Schaltenbrand WE, Costill DL (1988) Human Vitamin B-6 Pools Estimated Through Muscle Biopsies. Am J Clin Nutr 48: 291–294
Coburn SP (1996) Modeling vitamin B6 metabolism. Adv Food Nutr Res 40: 107–132
Coburn SP, Reynolds RD, Mahuren JD, Schaltenbrand WE, Wang Y, Ericson KL, Whyte MP, Zubovic YM, Ziegler PJ, Costill DL, Fink WJ, Pearson DR, Pauly TA, Thampy KG, Wortsman J (2002) Elevated Plasma 4-Pyridoxic Acid in Renal Insufficiency. Am J Clin Nutr 75: 57–64
Cohen M, Bendich A (1986) Safety of Pyridoxine (a Review of Human and Animal Studies. Toxicol Lett 34: 129–139
Dalton K, Dalton MJ (1987) Characteristics of pyridoxine overdose neuropathy syndrome. 76: 8–11
Davis SR, Scheer JB, Quinlivan EP, Coats BS, Stacpoole PW, Gregory JF (2005) Dietary vitamin B-6 restriction does not alter rates of homocysteine remethylation or synthesis in healthy young women and men. Am J Clin Nutr 81: 648–655
Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939–950
Dierkes J, Weikert C, Klipstein-Grobusch K, Westphal S, Luley C, Möhlig M, Spranger J, Boeing H (2007) Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort. Am J Clin Nutr 86: 214–220
DiSorbo DM, Phelps DS, Ohl VS, Litwack G (1980) Pyridoxine deficiency influences the behaviour of the glucocorticoid receptor complex. J Biol Chem 255: 3866–3870
Friso S, Girelli D, Martinelli N, Olivieri O, Lotto V, Bozzini C, Pizzolo F, Faccini G, Beltrame F, Corrocher R (2004) Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. Am J Clin Nutr 79: 992–998
Glenn GM, Krober MS, Kelly P, McCarty J, Weir M (1995) Pyridoxine as therapy in theophylline induced seizures. Vet Human Toxicol 37: 342–245
Gregory JF, Kirk JR (1981) Bioavailibility of Vitamin B6 in Foods. Nutr Res 39: 1–8
Hansen CM, Leklem JE, Miller LT (1996) Vitamin B6 status of women with a constant intake of vitamin B6 changes with three levels of dietary protein. J Nutr 126: 1891–1901
Hansson O, Sillanpaa M (1976) Pyridoxin and serum concentration of phenytoin and phenobarbitone. Lancet 1: 256
Henderson JM, Scott SS, Merrill AH, Hollins B, Kutner MH (1989) Vitamin B6 Repletion in Cirrhosis With Oral Pyridoxine: Failure to Improve Amino Acid Metabolism. Hepatology 9: 582–588
Holley J, Bender DA, Coulson WF, Symes EK (1983) Effects of vitamin B6 nutritional status on the uptake of [3H]oestradiol into the uterus, liver and hypothalamus of the rat. J Steroid Biochem 18: 161–165
Holmes RP, Assismos DG (1998) Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol 160: 1617–1624
Jain SK, Lim G (2001) Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+/K+)-ATPase activity reduction in high-glucose-treated human erythrocytes. Free Radic Biol Med 30: 232–237
Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH (1993) Metabolic Evidence that Deficiencies of Vitamin B-12 (Cobalamin), Folate, and Vitamin B-6 Occur Commonly in Elderly People. Am J Clin Nutr 58: 468–476
Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R, Furie KL (2003) Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 34: E51–E54
Kok FJ, Schrijver J, Hofman A, Witteman JC, Kruyssen DA, Remme WJ, Valkenburg HA (1989) Low Vitamin B6 Status in Patients with Acute Myocardial Infarction. Am J Cardiol 63: 513–516
Krinke GJ, Fitzgerald RE (1988) The pattern of pyridoxine-induced lesion: differences between the high and low toxic level. Toxicology 49: 171–178
Levene CI, Murray JC (1977) The Aetiological Role of Maternal Vitamin B6 Deficiency in the Development of Atherosclerosis. Lancet 1: 628–629
Löwik MR, van den Berg H, Westenbrink S, Wedel M, Schrijver J, Ockhuizen T (1989) Dose-Response Relationships Regarding Vitamin B6 in Elderly People: A Nationwide Nutritional Survey (Dutch Nutritional Surveillance System). Am J Clin Nutr 50: 391–399
Lumeng L (1978) The Role of Acetaldehyde in Mediating the Deleterious Effect of Ethanol on Pyridoxal 5′-Phosphate Metabolism. J Clin Invest 62: 286–293
Meltzer DI (2000) Selections from current literature complementary therapies for nausea and vomiting in early pregnancy. Practice 17: 570–573
Meydani SN, Ribaya-Mercado JD, Russell RM, Sahyoun N, Morrow FD, Gershoff SN (1991) Vitamin B6 Deficiency Impairs Interleukin-2 Production and Lymphocyte Proliferation in Elderly Adults. Am J Clin Nutr 53: 1275–1280
Midttun O, Hustad S, Schneede J, Vollset SE, Ueland PM (2007) Plasma vitamin B6 forms and their relation to transsulfuration metabolites in a large, population-based study. Am J Clin Nutr 86: 131–138
Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13: 2478–2487
Mydlik M, Derzsiova K, Zemberova E (1997) Metabolism of vitamin B6 and its requirement in chronic renal failure. Kidney Int 62: S56–S59
Nascimento MM, Suliman ME, Murayama Y, Nihi M, hayashi SY, Stenvinkel P, Riella MC, Lindholm B (2006) Effect of high-dose thiamine and pydidoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. J Renal Nutr 16: 119–124
Rall LC, Meydani SN (1993) Vitamin B6 and Immune Competence. Nutr Rev 51: 217–225
Reinken L, Ziegleauer H, Berger H (1976) Vitamin B6 Nutriture of Children with Acute Celiac Disease, Celiac Disease in Remission and of Children with Normal Duodenal Mucose. Am J Clin Nutr 29: 750–753
Scientific Committee on Food-SCF (1993) Reports of the Scientific Committee for Food (31st Series). Nutrient and energy intakes for the European Community. Available under: http://ec.europa.eu/food/fs/sc/scf/reports_en.html
Scientific Committee on Food-SCF (2000) Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin B6 (2000) European Commission. Available under: http://ec.europa.eu/food/fs/sc/scf/out80_en.html
Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland PM, Rubba P, Palma-Reis R, Meleady R, daly L, Witteman J, Graham I (1998) Low Circulating Folate and Vitamin B6 Concentrations. Risk Factors for Stroke, Peripheral Vascular Disease, and Coronary Artery Disease. Circulation 97: 437–443
Roubenoff R, Selhub J, Nadeau MR, Cannon JG, Freeman LM, Dinarello CA, Rosenberg IH (1995) Abnormal Vitamin B6 Staus in Rheumatoid Cachexia: Association With Spontaneous Tumor Necrosis Factor Alpha Production and Markers of Inflammation. Arthritis Rheum 38: 105–109
Said HM, Ortiz A, Vaziri ND (2002) Mechanism and regulation of vitamin B6 uptake by renal tubular epithelia: studies with cultured OK cells. Am J Physiol Renal Physiol 282: 465–471
Schaumburg H, Kaplan J, Windeband A, Vick N, Rasmus S, Pleasure D, Brown MJ (1983) Sensory neuropathy from pyridoxine abuse. N Engl J Med 309: 445–448
Solomon LR, Cohen K (1989) Erythrocyte O2 transport and metabolism and effects of vitamin B6 theapy in type II diabetes mellitus. Diabetes 38: 881–886
Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of Serum Cystathionine Levels in Patients with Cobalamin and Folate Deficiency. Blood 81: 3404–3413
Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826–2832
Subbarao K, Kakkar VV (1979) Pyridoxal 5′-Phosphate: a New Physiological Inhibitor of Blood Coagulation and Platelet Function. Biochem Pharmacol 28: 531–534
Tsuge H, Hotta N, Hajakawa T (2000) Effects of Vitamin B6 on (n-3) Polyunsaturated Fatty Acid Metabolism. J Nutr 130: S333–334S
Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJ (1996) The Effect of a Subnormal Vitamin B6 Status on Homocysteine Metabolism. J Clin Invest 98: 177–184
Van Wyk V, Luus HG, Heyns AD (1992) The in Vivo Effect in Humans of Pyridoxal-5′-Phosphate on Platelet Function and Blood Coagulation. Thromb Res 66: 657–668
Voziyan PA, Hudson BG (2005) Pyridoxamine. The many virtues of a Maillard reaction inhibitor. Ann N Y Acad Sci 1043: 80–816
Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR (1995) Mice lacking tissue-nonsprecific alkaline phosphatase die from seizures due to defective metabolism of vitamin B6. Nat Genet 11: 45–51
Wilcken DE, Wilcken B (1997) The Natural History of Vascular Disease in Homocystinuria and the Effects of Treatment. J Inherit Metab Dis 20: 295–300
Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER (2001) Vascular Outcome in Patients with Homocystinuria due to Cystathionine Beta-Synthase Deficiency Treated Chronically. A Multicenter Observational Study. Arterioscler Thromb Vasc Biol 21: 2080–2085
Literaturverzeichnis
Andres E, Perrin AE, Demangeat C, Kurtz JE, Vinzio S, Grunenberger F, Goichot B, Schlienger JL (2003) The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine. Eur J Intern Med 14: 221–226
Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V (2000) Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23: 1227–1231
Bose S, Seetharam S, Seetharam B (1995) Membrane expression and interactions of human transcobalamin II receptor. J Biol Chem 270: 8152–8157
Carmel R, Karznaze DS (1985) The deoxyuridine suppression test identifies subtle cobalamin deficiency in patients without typical megaloblastic anemia. J Am Med Assoc 253: 1284–1287
Carmel R, Sinow RM, Siegel ME, Samloff IM (1988) Food cobalamin malabsorption occurs frequently in patients with unexplained low serum cobalamin levels. Arch Intern Med 148: 1715–1719
Carmel R (1996) Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 156: 1097–1100
Carmel R (1997) Cobalamin, the stomach and aging. Am J Clin Nutr 66: 350–359
Chanarin I, Deacon R, Lumb M, Muir M, Perry J (1985) Cobalamin-folate interrelations: a critical review. Blood 66: 479–489
Chanarin I, Stephenson E (1988) Vegetarian diet and cobalamin deficiency: their association with tuberculosis. J Clin Path 41: 759–762
Cohen H, Weinstein WM, Carmel R (2000) The heterogeneity of gastric histology and function in food malabsorption: absence of atrophic gastritis and achlorhydria in some patients with severe malabsorption. Gut 47: 638–645
Cooperman JM, Pesci-Bourel A, Luhby AL (1970) Urinary excretion of folic acid activity in man. Clin Chem 16: 375–378
Doscherholmen A, Ripley D, Chang S, Silvis SE (1977) Influence of age and stomach function on serum vitamin B12 concentration. Scand J Gastroenterol 12: 313–319
Fowler B (1998) Genetic defects of folate and cobalamin metabolism. Eur J Pediatr 157: S60–S66
Funada U, Wada M, Kawata T, Mori K, Tamai H, Kawanishi T, Kunou A, Tanaka N, Tadokoro T, Maekawa A (2000) Changes in CD4+CD8-/CD4-CD8+ ratio and humoral immune functions in vitamin B12-deficient rats. Int J Vitam Nutr Res 70: 167–171
Haddad EH, Berk LS, Kettering JD, Hubbard RW, Peters WR (1999) Dietary intake and biochemical, hematologic, and immune status of vegans compared with nonvegetarians. Am J Clin Nutr 70: 586S–593S
Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J (1991) Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 70: 229–245
Herbert V (1988) Vitamin B12: plant sources, requirements, and assay. Am J Clin Nutr 48: 852–858
Herbert V (1994) Staging vitamin B-12 (cobalamin) status in vegetarians. Am J Clin Nutr 59: 1213S–1222S
Herrmann W, Schorr H, Obeid R, Geisel J (2003) Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. Am J Clin Nutr 78: 131136
Herzlich B, Herbert V (1988) Depletion of serum holotranscobalamin II: an early sign of negative vitamin B12 balance. Lab Invest 58: 332–337
Institute of Medicine (1998) Panel on Folate, Other B Vtamins, and Choline. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. National Academy Press, Washington D. C., pp 306–356
Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH (1993) Metabolic Evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 58: 468–476
Kanazawa S, Herbert V (1985) Total corrinoid, cobalamin (vitamin B12), and cobalamin analogue levels may be normal in serum despite cobalamin depletion in liver in patients with alcoholism. Lab Invest 53: 108–110
Kozyraki R, Kristiansen M, Silahtaroglu A, Hansen C, Jacobsen C, Tommerup N, Verroust PJ, Moestrup SK (1998) The human intrinsic factor-vitamin B12 receptor, cubilin: molecular characterization and chromosomal mapping of the gene to 10 p within the autosomal recessive megaloblastic anemia (MGA1) Region. Blood 91: 3593–3600
Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J (1998) Effective treatment of cobalamin deficiency with oral cobalamin. Blood 92: 1191–1198
Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, Marcell PD, Stabler SP, Allen RH (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318: 1720–1728
Lindenbaum J, Savage DG, Stabler SP, Allen RH (1990) Diagnosis of cobalamin deficiency II: relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 34: 99–107
Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH (1994) Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Invest 60: 2–11
Louwman MW, van Dusseldorp M, van de Vijver FJ, Thomas CM, Schneede J, Ueland PM, Refsum H, van Staveren WA (2000) Signs of impaired cognitive function in adolescents with marginal cobalamin status. Am J Clin Nutr 72: 762–769
Majchrzak D, Singer I, Männer M, Rust P, Genser D, Wagner KH, Elmadfa I (2006) B-vitamin status and concentrations of homocysteine in Austrian omnivores, vegetarians and vegans. Ann Nutr Metab 50: 485–491
Marcuard SP, Albernaz L, Khazanie PG (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211–215
Nexo E, Hvas AM, Bleie O, Refsum H, Fedosov SN, Vollset SE, Schneede J, Nordrehaug JE, Ueland PM, Nygard OK (2002) Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. Clin Chem 48: 1768–1771
Nexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN (2002) Quantification of holo-transcobalamin, a marker of vitamin B12 deficiency. Clin Chem 48: 561–562
Platica O, Janeczko R, Quadros EV, Regec A, Romain R, Rothenberg SP (1991) The cDNA sequence and the deduced amino acid sequence of human transcobalamin II show homology with rat intrinsic factor and human transcobalamin I. J Biol Chem 66: 7860–7863
Schneede J, Dagnelie PC, van Staveren WA, Vollset SE, Refsum H, Uelnad PM (1994) Methylmalonic acid and homocysteine in plasma as indicators of functional cobalamin deficiency in infants on macrobiotic diets. Pediatr Res 36: 194–201
Specker BL, Black A, Allen L, Morrow F (1990) Vitamin B12: low milk concentrations are related to low serum concentrations in vegetarian women and to methylmalonic aciduria in their infants. Am J Clin Nutr 52: 1073–1076
Skacel PO, Chanarin I (1983) Impaired chemiluminescence and bactericidal killing by neutrophils from patients with severe cobalamin deficiency. Br J Haematol 55: 203–215
Stabler SP, Allen RH, Savage DH, Lindenbaum J (1990) Clinical spectrum and diagnosis of cobalamin deficiency. Blood 76: 871–881
Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81: 3404–3413
Thomas L (2005) Labor und Diagnose. 6. Auflage, TH-Books Verlagsgesellschaft mbH, Frankfurt
Toh BH, van Driel IR, Gleeson PA (1997) Pernicious Anemia. N Engl J Med 337: 1441–1448
Van Asselt DZ, de Groot LC, van Staveren WA, Blom HJ, Wevers RA, Biemond I, Hoefnagels WH (1998) Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older dutch subjects. Am J Clin Nutr 68: 328–334
Vant Sant P, Küsters PF, Harthoorn-Lasthuizen EJ (1997) Dependency of MCV and hemoglobin concentration on plasma vitamin B12 levels in relation to sex and age. Clin Lab Haematol (1997) 19: 27–31
Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ (2000) Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphozyte DNA hypomethylation. J Biol Chem 275: 29318–29323
Literaturverzeichnis
Bailey LB (1990) Folate status assessment. J Nutr 120: 1508–1511
Bird OD, Pfiffner JJ (1956) Water-soluble vitamins. I. Vitamin B12, folic acid, choline, and para-aminobenzoic acid. Annu Rev Biochem 25: 397–434
Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN (1997) Folate deficiency causes uracil misincorporation into human DNA and chrososome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94: 3290–3295
Brouwer DA, Welten HT, Reijngoud DJ, van Doormaal JJ, Muskiet FA (1998) Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine. Clin Chem 44: 1545–1550
Castenmiller JJ, van de Poll CJ, West CE, Brouwer IA, Thomas CM, van Dusseldorp M (2000) Bioavailability of folate from processed spinach in humans. Effect of food matrix and interaction with carotenoids. Ann Nutr Metab 44: 163–169
Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, Blom HJ, Jakobs C, Tavares de Almeida I (2003) Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. Clin Chem 49: 1292–1296
Chen Z, Karaplis AC, Ackerman SL, Pogribny IP, Melnyk S, Lussier-Cacan S, Chen MF, Pai A, John SW, Smith RS, Bottiglieri T, Bagley P, Selhub J, Rudnicki MA, James SJ, Rozen R (2001) Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, withneuropathology and aortic lipid deposition. Hum Mol Genet 10: 433–443
Choi SW, Mason JB (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129–132
Craven PA, DeRubertis FR (1992) Alterations in protein kinase C in 1,2-dimethylhydrazine induced colonic carcinogenesis. Cancer Res 52: 2216–2221
DaCosta KA, Cochary EF, Blusztajn JK, Garner SC, Zeisel SH (1993) Accumulation of 1,2-sn-diacylglycol with increased membrane-associated protein kinase C may be the mechanism for spontaneous hepatocarcinogenesis in choline deficient rats. J Biol Chem 268: 2100–2105
De Bree A, van Dusseldorp M, Brouwer IA, van der Hof KH, Steegers-Theunissen RP (1997) Folate intake in Europe: recommended, actual and desired intake. Eur J Clin Nutr 51: 643–660
Dong C, Yoon W, Goldschmidt-Clermont PJ (2002) DNA methylation and atherosclerosis. J Nutr 132: 2406–2409
Donnelly JG (2001) Folic acid. Crit Rev Clin Lab Sci 38: 183–223
Douchette MM, Stevens VL (2001) Folate receptor function is regulated in response to different cellular growth rates in cultured mammalian cells. J Nutr 131: 2819–2825
Duthie SJ, Hawdon A (1998) DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro. FASEB J 12: 1491–1497
Elmadfa I, Freisling H, König J, Blachfelner J, Cvitkovich-Steiner H, Genser D, Grossgut R, Hassan-Hauser C, Kichler R, Kunze M, Majchrzak D, Manafi M, Rust P, Schindler K, Vojir F, Wallner S, Zilberszac A (2003) Österreichischer Ernährungsbericht 2003. Institut für Ernährungswissenschaften der Universität Wien, 1. Auflage, Wien
Fenech M (2001) The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat Res 475: 57–67
Giles WH, Kittner SJ, Croft JB, Anda RF, Casper ML, Ford ES (1998) Serum folate and risk for coronary heart disease: results from a cohort of US adults. Ann Epidemiol 8: 490–496
Gonzalez-Gross M, Prinz-Langenohl R, Pietrzik K (2002) Folate status in Germany 1997–2000. Int J Vitam Res 72: 351–359
Halsted CH (1979) The intestinal absorption of folates. Am J Clin Nutr 32: 846–855
Henning SW, Swendseid ME, Ivandic BT, Liao F (1997) Vitamins C, E and A and heme oxygenase in rats fed methyl/folate-deficient diets. Free Rad Biol Med 23: 936–930
Herschel KM, Snell EE, Williams RJ (1941) The concentration of „folic acid“ J Am Chem Soc 63: 44–51
Hutto BR (1997) Folate and cobalamin in psychiatric illness. Compr Psychiatry 38: 305–314
Institute of Medicine, National Research Council (1998) Dietary reference intakes: folate, other B vitamins and choline. National Academy Press, Washington, D. C.
Jacob RA, Wu MM, Henning SM, Swendseid ME (1994) Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 124: 1072–1080
Kane MA, Portillo RM, Antony AC, Kolhouse JF (1986) The interrelationship of the soluble and membrane-associated folate-binding proteins in human KB cells. J Biol Chem 26: 15625–15631
Kim YI, Pogribny IP, Basnakian AG, Miller JW, Selhub J, James SJ, Mason JB (1997) Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 65: 46–52
Krumdieck CL, Fukushima K, Fukushima T, Shiota T, Butterworth CE (1978) A long-term study of the excretion of folate and pterins in a human subject after ingestion of 14C folic acid, with observations on the effect of diphenylhydantoin administration. Am J Clin Nutr 31: 88–93
Leonhardt H, Cardoso MC (2000) DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem 35: 78–83
Lewis CJ, Crane NT, Wilson DB, Yetley EA (1999) Estimated folate intakes: data updated to reflect food fortification, increased bioavailibility, and dietary supplement use. Am J Clin Nutr 70: 198–207
Lindenbaum J, Nath BJ (1980) Megaloblastic anemia and neutrophil hypersegmentation. Br J Haematol 44: 511–513
Loria CM, Ingram DD, Feldman JJ, Wright JD, Madans JH (2000) Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 160: 3258–3262
Mason JB, Levesque T (1996) Folate: effects on carcinogenesis and the potential for cancer chemoprevention. Oncology 10: 1727–1744
Mastropaolo W, Wilson MA (1993) Effect of light on serum B12 and folate stability. Clin Chem 39: 913
Metz J (1984) The deoxyuridine suppression test. Crit Rev Clin Lab Sci 20: 205–241
Morrison HI, Schaubel D, Desmeules M, Wigle DT (1996) Serum folate and risk of fatal coronary heart disease. J Am Med Assoc 275: 1893–1896
Nakano E, Higgins JA, Powers HJ (2001) Folate protects against oxidative modification of human LDL. Br J Nutr 86: 637–639
Oakley GP (1998) Eat right and take a multivitamin. N Engl J Med 338: 1060–1061
Osborne CB, Lowe KE, Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. J Biol Chem 268: 21657–21664
Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG (1993) Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin In-Invest 91: 2497–2503
Pietrzik K, Golly I, Loew D (2008). Folsäure. Handbuch Vitamine für Prophylaxe, Beratung und Therapie. Urban&Fischer, Wien Berlin
Piyathilake CJ, Macaluso M, Hine RJ, Richards EW, Krumdieck CL (1994) Local and systemic effects of cigarette smoking on folate and vitamin B12. Am J Clin Nutr 60: 559–566
Provan D, Weatherall D (2000) Red cells II: aquired anaemias and polycythaemia. Lancet 355(9211): 1260–1268
Richardson BC (2002) Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 132: 2401–2405
Said HM, Nguyen TT, Dyer DL, Cowan KH, Rubin SA (1996) Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. Biochim Biophys Acta 1281: 164–172
Sauer H, Wilmanns W (1977) Cobalamin dependent methionine synthesis and methyl-trap in human vitamin B12 deficiency. Br J Haematol 36: 189–198
Schroeder HA (1971) Losses of vitamins and trace minerals resulting from processing and preservation of foods. Am J Clin Nutr 24: 562–573
Scott JM, Weir DG (2000) The methylfolate trap. Lancet 2: 337–340
Shane B, Carpenter KJ (1997) E. L. Robert Stokstad (1913–1995) J Nutr 127: 199–201
Sierra EE, Goldman ID (1999) Recent advances in the understanding of the mechanisms of membrane transport of folates and antifolates. Semin Oncol 26: 11–23
Sirotnak FM, Tolner B (1999) Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 19: 91–122
Stanger O (2002) Physiology of folic acid in health and disease. Curr Drug Metab 3: 211–223
Stanger O (2004) Homocystein. Grundlagen, Klinik, Therapie, Prävention. 1. Auflage, Verlag Wilhelm Maudrich, Wien-München-Bern
Stanger O, Hermann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M (2004) Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 93: 439–453
Stanger O, Weger M (2003) Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 41: 1444–1454
Steinberg SE, Campbell CL, Hillman RS (1979) Kinetics of the normal folate enterohepatic cycle. J Clin Invest 64: 83–88
Stockstad EL (1979) Early works with folic acid. Fed Proc 38: 2696–2698
Thomas L (2005) Labor und Diagnose. 6. Auflage, TH-Books Verlagsgesellschaft mbH, Frankfurt
Willis L (1931) Treatment of „pernicious anaemia of pregnancy“ and „tropical anaemia“ with special reference to yeast extract as curative agent. Br Med J 1: 1059–1064
Yu S, Morris JG (1998) Folate requirement of growing kittens to prevent elevated formiminoglutamic acid excretion following histidine loading. J Nutr 128: 2606–2608
Literaturverzeichnis
Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G (2007):Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 65: 1301–1311
Becker AM, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N (2005): Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. N Engl J Med 353: 2450–2461
BGVV (1999) Bundeslebensmittelschlüssel (BLS), version II.3. Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin (BGVV), Berlin
Campion EW, Glynn RJ, DeLabry LO (1987) Asymtomatic hyperuricemia. Risks and consequences in the Nor-Normative Aging Study. Am J Med 82: 421–6
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363(9417): 1277–1281
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350: 1093–1103
Choy G (2005) An update and the treatment options for gout and calcium pyrophosphate deposition. Expert Opin Pharmacother 6(14): 2443–2453
Cronstein BN, Terkeltaub R (2006) The inflammatory process of gout ant its treatment. Arthritis Res Ther 8(5): 405
Enomoto A, Endou H (2005) Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9: 195–205
Graessler J, Graessler A, Unger S, Kopprasch S, Tausche AK, Schroeder HE (2006) Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Causasion population. Arthritis Rheum 54: 292–300
Grusch B, Rintelen B, Leeb BF (2007) Evidenzbasierte Empfehlungen der „European League Against Rheumatism“ zur Diagnostik und Therapie der Gicht. Z Rheumatol 66: 568–572
Hagos Y, Stein D, Ugele B, Burkhardt G, Bahn A (2007) Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 18: 430–439
Heseker B, Heseker H (1999) Nährstoffe in Lebensmitteln: Die Große Energie-und Nährwerttabelle. Umschau-Zeitschrifen-Verlag, Breidenstein Frankfurt am Main
Hoskion TK, Wortmann RL (2006) Advances in the management of gout and hyperuricaemia. Scand J Rheu-Rheumatol 35(4): 251–260
Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G (2007) British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG): British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46(8): 1372–1374
Luk AJ, Simkin A (2005) Epidemiology of Hyperuricemia and Gout. Am J Manag Care 11: 435–442
Mertz DP (1987) Gicht im Spiegel der Jahrtausende. In: Mertz DP (Hrsg) Gicht. Thieme, Stuttgart New York, S 4–10
Mikuls TR (2007) Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 25: 114–119
Mikuls TR, Curtis JR, Allison JJ, Hicks RW, Saag KG (2006) Medication errors with the use of Allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system. J Rheumatol 33: 562–566
Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 64: 267–272
Montag A, Kölling I, Jänicke S, Benkmann R, Lou ShN (1989) Zur Kenntnis des Purinbasenendgehaltes in Lebensmitteln. Akt Ernähr 14: 243–247
Mount DB, Kwon CY, Zandi-Nejad K (2006) Renal urate transport. Rheum Dis Clin North Am 32: 313–331
Ordi J, Alonso PL, Zulueta Jd, Esteban J, Velasco M, Mas E, Campo E, Fernández PL (2006) The severe gout of holy roman emperor Charles V. N Eng J Med 3555: 515–520
Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM (2006) Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering theapy: a prospective study. Arthritis Rheum 55(5): 786–790
Ruilope LM, Garcia-Puig J (2001) Hyperuricemia and Renal Funktion. Current Hypentension Reports 3: 197–202
Saag KG, Choi H (2006) Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 8(Suppl 1) S2: 1–14
Schlesinger N (2004) Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 64(21): 2399–2416
Schröder HE (1993) Gicht. In: Hartmann F, Philipp T (Hrsg) Klinik der Gegenwart. Urban & Schwarzenberg, München, S 1–48
So A (2007) Neue Erkenntnisse zur Pathophysiologie und Therapie der Gicht. Z Rheumatol 66: 562–567
Steele TH (1999) Hyperuricemic nephropathies. Nephron 81: 45–49
Tausche AK, Aringer M, Schröder HE, Bornstein R, Wunderlich C, Wozel G (2008) The Janus Faces of Allopurinol-Allopurinol Hypersensitivity Syndrome. Am J Med 121(3): e3–4
Tausche AK, Unger S, Richter K, Wunderlich C, Gräßler J, Roch B, Schröder HE (2006) Hyperurikämie und Gicht. Internist 47: 509–522
Terkeltaub R (2006) Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis 64(1–2): 82–86
Thiele P, Heidelmann G, Schröder HE (1986) Hyperurik-ämie und Gicht. Fischer, Jena
Unger S, Tausche AK, Kopprasch S, Bornstein SR, Aringer M, Gräßler J (2007) Molekulare Grundlagen der primär-renalen Hyperurikämie, zur Rolle des humanen Urattransportes hURAT1. Z Rheumatol 66: 556–561
Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics 40(4): 437–442
Winzer M, Grässler J, Ahringer M (2007) Kristallarthropathien — alt, aber wichtig. Z Rheumatol 66: 317–325
Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312–1324
Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1301–1311
Literaturverzeichnis
Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E (1999) Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 106: 179–184
Bigaard J, Tjønneland A, Thomsen BL, Overvad K, Heitmann BL, Sørensen TI (2003) Waist circumference, BMI, Smoking, and Mortality in Middle-aged Men and Women. Obesity Research 11: 895–903
Canadian Diabetes Association (2008) Clinical Practice Guidelines fort he Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes 32(suppl 1): 1–201
Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R (2004) Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 17: 222–229
El-Giamal N, de Zwaan M, Bailer U, Strnad A, Schüssler P, Kasper S (2008) Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. Eur Neuropsychopharmacol 13(2): 73–79
Elliott SS, Keim NL, Stern JS, Teff K, Havel PJ (2002) Fructose, weight gain, and the insulin resistance syndrome. American Journal of Clinical Nutrition 76: 911–922
Görzer E, Wamser K, Tscherner D, Toplak H (2007) The effect of a VLCD programme using INSUmed on fat mass in patients with BMI above 29 — a comparison of type 2 diabetic and non diabetic patients. Int J Obes 31: S166–S166
Goodman E, Whitaker RC (2002) A prospective study of the role of depression in the development and persistence of adolescent obesity. Pediatrics 110(3): 497–504
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119–2125
Javaras KN, Pope HG, Lalonde JK, Roberts JL, Nillni YI, Laird NM, Bulik CM, Crow SJ, McElroy SL, Walsh BT, Tsuang MT, Rosenthal NR, Hudson JI (2008) Co-occurence of binge eating disorder ith psychiatric and medical disorders. J Clin Psychiatry 69: 266–273
Karam-Hage M, Cinciripini PM (2007) Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists. Curr Oncol Rep 9: 509–516
Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R (2006) Visceral fati s an independent predictor of all-cause mortality in men. Obesity 14: 336–341
Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW (2006) Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 60: 906–910
Noma S, Uwatoko T, Yamamoto H, Hayashi T (2008) Effect of milnacipran on binge eaiting–a pilot study. Neuropsych Dis Treat 4: 295–300
Pi-Sunyer FX (2008) The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 120: 5–17
Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Stastny J, Thierry N, Lenzinger E, Kasper S (2001) Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. J Affect Disord 63: 239–242
Rosenstock J, Hollander P, Chevalier S, Iranmanesh A; SERENADE Study Group (2008) SERENADE: the Study Evaluating Rimonabant Efficacy in Drugnaive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 31: 2169–2176
Scheeen HJ (2008) CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 20Suppl 1: 139–146
Serrano-Rios M, Melchionda N, Moreno-Carretero E; Spanish Investigators (2002) Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19: 119–124
Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators (2008) Blood pressure changes associated with sibutramine and weight management — an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT) Diabetes Obes Metab [Epub ahead of print]
Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8): 741–752
Suter PM (2005) Is alcohol consumption a risk factor for weight gain and obesity? Crit Rev Clin Lab Sci 42: 197–227
Toplak (2002) Praxishandbuch Adipositas. Springer, Wien New York
Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L (2005) X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 7: 699–708
Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1): 138–46
Toplak (2008) Update: Das Metabolische Syndrom. J Kardiol 15: 243–246
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155–161
Van Gaal LF, Broom JI, Enzi G, Toplak H (1998) Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 54: 125–132
Literatur
AGA — Arbeitsgemeinschaft Adipositas im Kindes und Jugendalter (2006) Leitlinien zur Diagnostik, Therapie und Prävention der Adipositas. www.a-g-a.de [18. 12. 2008]
Allard P, Delvin EE, Paradis G, Hanley JA, O’Loughlin J, Lavallée C, Levy E, Lambert M (2003) Distribution of fasting plasma insulin, free fatty acids, and glucose concentrations and of homeostasis model assessment of insulin resistance in a representative sample of Quebec children and adolescents. Clin Chem 49: 644–649
Alexy U, Clausen K, Kersting M (2008) Die Ernährung gesunder Kinder und Jugendlicher nach dem Konzept der Optimierten Mischkost, Ernährungs-Umschau 3/08: 168–175
Bös K, Opper E, Woll A, Liebisch R, Breithecker D, Kremer B (2001) Fitness in der Grundschule. Haltung und Bewegung 21: 4–67
Clément K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougnères P, Lebouc Y, Froguel P, Guy-Grand B (1998) A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392: 398–401
Dale D, Corbin CB, Dale KS (2000) Restricting opportunities to be active during school time: do children compensate by increasing physical acitivity levels after school? Res Q Exerc Sport 71: 240–248
Danone Nutrition Forum (2008) http://www.danone.at/index.php?id=danone-presse [18. 12. 2008]
Dietz WH, Robinson TN (2005) Overweight children and adolescents. New Engl J Med 352: 2100–2109
Düren M, Kersting M (2003) Das Angebot an Kinderlebensmitteln in Deutschland: Produktübersicht und ernährungsphysiologische Wertung. Ernährungsumschau 15: 16–21
Ebbeling CB, Pawlak DB, Ludwig DS (2002) Childhood obesity: public-health crisis, common sense cure. Lancet 360: 473–482
Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415–1428
Epstein LH, Roemmich JN, Robinson JL, Paluch RA, Winiewicz DD, Fuerch JH, Robinson TN (2008) A randomized trial of the effects of reducing television viewing and computer use on body mass index in young children. Arch Pediatr Adolesc Med 162: 239–245
Erickson SJ, Robinson TN, Haydel KF, Killen JD (2000) Are overweight children unhappy?: Body mass index, depressive symptoms, and overweight concerns in elementary school children. Arch Pediatr Adolesc Med 154: 931–935
Farooqi IS, O’Reilly M (2000) Recent advances in the genetics of severe childhood obesity. Arch Dis Child 83: 31–34
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348: 1085–1095
Field AE, Camargo CA Jr, Taylor CB, Berkey CS, Frazier AL, Gillman MW, Colditz GA (1999) Overweight, weight concerns, and bulimic behaviors among girls and boys. J Am Acad Child Adolesc Psychiatry 38: 754–760
Gortmaker SL, Must A, Sobol AM, Peterson K, Colditz G, Dietz W (1996) Television viewing as a cause of increasing obesity among children in the United States 1987–1990. Arch Ped Adolesc Med 150: 356–362
Hales CN, Barker DJP (2001) The thrifty phenotype hypothesis. Brit Med Bull 60: 5–20
Harnack L, Stang J, Story M (1999) Soft drink consumption among US Children and adolescents: nutritional consequences. J Am Diet Ass 4: 436–441
Hrebícek J, Janout V, Malincíková J, Horáková D, Cízek L (2002) Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 87: 144–147
Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L (2001) Cardiovascular Morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689
Jauschnegg S, Meisinger B, Karall D, Scholl-Bürgi S (2008) Adi Positaz sucht die Pyramiden. Im Druck.
Kolbe H, Räkel-Rehner S (2003) Übergewicht und Adipositas. Praktische Diätetik in der Pädiatrie, SPS-Verlagsgesellschaft, Heilbronn, S 48–51
Kromeyer-Hauschild K, Wabitsch M, Kunze D, Geller F, Geiß HC, Hesse V, von Hippel A, Jaeger U, Johnsen D, Korte W, Menner K, Müller G, Müller JM, Niemann-Pilatus A, Remer T, Schaefer F, Wittchen H-U, Zabransky S, Zellner K, Ziegler A, Hebebrand J (2001) Perzentile für den Body-mass-Index für das Kindes-und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilk 2001;149:807–814
Kurth BM, Schaffrath RA (2007) The prevalence of overweight and obese children and adolescents living in Germany. Results of the German Health Interview and Examination Survey for Children and Adolescents (KIGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50: 736–743
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155–157
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O’Rahilly S (1997) Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature 387: 903–908
Mensink GMB, Burger M (2004) Was isst Du? Bundesge-sundheitsbl Gesundheitsforsch Gesundheitsschutz 47: 219–226
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114: 555–576
Reinehr T (2007) Entstehung von Übergewicht und Adipositas: Ursachen, Hintergründe und Folgen. Medizinische Hintergründe. In: Graf C, Dordel S, Reinehr T (Hrsg) Bewegungsmangel und Fehlernährung bei Kindern und Jugendlichen. Deutscher Ärzteverlag, 2007
Strauss RS, Barlow SE, Dietz WH (2000) Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 136: 727–733
Strauss RS (2000) Childhood obesity and self-esteem. Pediatrics 105: e15
Wabitsch M (2006) Medikamente. In: Reinehr T, Wabitsch M (Hrsg) Adipositas in Praxi. Multimodale Konzepte für das Kindes-und Jugendalter. Hans Marseille Verlag GmbH, München
Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S (2004) Obesity and the metabolic syndrome in children and adolescents. New Engl J Med 350: 2362–374
Wills M (2004) Orthopedic complications of childhood obesity. Pediatr Phys Ther 16: 230–235
WHO — World Health Organization (1998) Report of a WHO Consultion on Obesity. Obesity — Preventing and managing a global epidemic. WHO, Genf
Zimmermann MB, Gübeli C, Püntener C, Molinari L (2004) Overweight and obesity in 6–12 year old children in Switzerland. Swiss Med Wkly 134: 523–528
Literaturverzeichnis
Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB (1999) Annual deaths attributable to obesity in the United States. JAMA 282:1530–1538
Angrisani L, Furbetta F, Doldi SB, Basso N, Lucchese M, Giacomelli F, Zappa M, Di Cosmo L, Veneziani A, Turicchia GU, Alkilani M, Forestieri P, Lesti G, Puglisi F, Toppino M, Campanile F, Capizzi FD, D’Atri C, Sciptoni L, Giardiello C, Di Lorenzo N, Lacitignola S, Belvederesi N, Marzano B, Bernate P, Iuppa A, Borrelli V, Lorenzo M (2003) Lap Band adjustable gastric banding system: the Italian experience with 1863 patients operated on 6 years. Surg Endosc 17: 409–412
Baltasar A, Bou R, Miró J, Bengochea M, Serra C, Pérez N (2002) Laparoscopic biliopancreatic diversion with duodenal switch: technique and initial experience. Obes Surg 12: 245–248
Cigaina VV, Saggioro A, Rigo VV, Pinato G, Ischai S (1996) Long-term effects of gastric pacing to reduce feed intake in swine. Obes Surg 6: 250–253
Cigaina V (2002) Gastric pacing as therapy for morbid obesity: preliminary results. Obes Surg 12: 12–16
Eckhout GV, Willbanks OL, Moore JT (1986) Vertical ring gastroplasty for morbid obesity: five year experience with 1,463 patients. Am J Surg 152: 713–716
Feng JJ, Gagner M (2002) Laparoscopic biliopancreatic diversion with duodenal switch. Semin Laparosc Surg 9: 125–129
Forsell P, Hellers G (1997) The Swedish adjustable gastric banding (SAGB) for morbid obesity — nine year experience and four year follow up of patients operated with a new adjustable band. Obes Surg 7: 345–351.
Kuzmak L (1986) Silicone gastric banding: a simple and effective operation for morbid obesity. Contemp Surg 28: 13–18
Hallberg D, Forsell P (1985) Ballongband vid behandling av massiv övervikt. Svensk Kirurgi 43: 106–111
Health implications of obesity (1985) National Institutes of Health Consensus Development Conference Statement. Ann Intern Med 103: 1073–1077
Higa KD, Ho T, Boone KB (2001) Laparoscopic Roux-en-Y gastric bypass: technique and 3-year follow-up. J Laparoendosc Adv Surg Tech A 11: 377–382
Himpens J, Dapri G, Cadière GB (2006) A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg 16: 1450–1456
International Association for the Study of Obesity (IASO). Newsletter 4/1997
Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, Schindler K, Luger A, Ludvik B, Prager G (2005) Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 15: 1024–1029
Lonroth H, Dalenback J, Haglind E, Lundell L (1996) Laparoscopic gastric bypass. Surg Endosc 10: 636–638
Mason EE, Ito C (1967) Gastric bypass in obesity. Surg Clin North Am 47: 1345–1351
Mason EE (1982) Vertical banded gastroplasty for obesity. Arch Surg 117: 701–706
Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N (2007) Sleeve gastrectomy: a restrictive procedure? Obes Surg 17: 57–62
Mittermair RP, Weiss H, Nehoda H, Kirchmayr W, Aigner F (2003) Laparoscopic Swedish adjustable gastric banding: 6-year follow-up and comparison to other laparoscopic bariatric procedures. Obes Surg 13: 412–417
Mittermair RP, Weiss H, Nehoda H, Aigner F (2002) Uncommon intragastric migration of the Swedish adjustable gastric band. Obes Surg 12: 372–375
Mittermair RP, Weiss HG, Nehoda H, Peer R, Donnemiller E, Moncayo R, Aigner F (2003) Band leakage after laparoscopic adjustable gastric banding. Obes Surg 13: 913–917
Morino M, Toppino M, Bonnet G, Rosa R, Garrone C (2002) Laparoscopic vertical banded gastroplasty for morbid obesity. Surg Endosc 16: 1566–572
Näslund E, Freedman J, Lagergren J, Stockeld D, Granström L (1999) Three-year results of laparoscopic vertical banded gastroplasty. Obes Surg 9: 369–373
National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. National Heart, Lung, and Blood Institute. Obes Res 1998; 6Suppl 2: 51S–209S
National Institutes of Health (1985) Health implications of obesity. Cosensus Develpoment Conference Statement. Ann Intern Med 103: 1073–1077
Nguyen NT, Goldman C, Rosenquist CJ, Arango A, Cole CJ, Lee SJ, Wolfe BM (2001) Lapaoroscopic versus open gastric bypass: a randomized study of out comes, quality of life, and costs. Ann Surg 234: 279–291
Olbers T, Lönroth H, Dalenbäck J, Haglind E, Lundell L (2001) Laparoscopic vertical banded gastroplasty — an effective long-term therapy for morbidly obese patients? Obes Surg 11: 726–730
Rubenstein RB (2002) Laparoscopic adjustable gastric banding at a US center with up to 3-year follow-up. Obes Surg 12: 380–384
Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J (2000) Outcome after laparoscopic Roux-en-y gastric bypass for morbid obesity. Ann Surg 4: 515–529
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660–1672
Scopinaro N, Gianetta E, Adami GF, Friedman D, Traverso E, Marinari GM, Cuneo S, Vitale B, Ballari F, Colombini M, Baschieri G, Bachi V (1996) Biliopancreatic diversion for obesity at eighteen years. Surgery 119: 261–268
Scopinaro N, Gianetta E, Pandolfo N, Anfossi A, Berretti B, Bachi V (1976) Bilio-pancreatic bypass: proposal and preliminary experimental study of a new type of operation for the functional surgical treatment of obesity. Minerva Chir 31: 560–566
Wittgrove AC, Clark GW, Tremblay LJ (1994) Laparoscopic gastric bypass, Roux-en-Y: Preliminary report of five cases. Obes Surg 4: 353–357
Wolf AM (1998) What is the economic case for treating obesity? Obesity Res 6: 2–7
Literaturverzeichnis
Bloomberg RD, Fleishman A, Nalle JE, Herron DM, Kini S (2005) Nutritional Deficiencies following Bariatric Surgery: What have we learned? Obes Surg 15: 145–154
Brolin RE, Gorman JH, Gorman RC, Petschenik AJ, Bradley LJ, Kenler HA, Cody RP (1998) Are vitamin B12 und folate deficiency clinically important after roux-en-Y gastric bypass? J Gastrointest Surg 2: 436–442
Carrasco F, Papapietro K, Csendes A, Salazar G, Echenique C, Lisboa C, Diaz E, Rojas O (2007) Changes in resting energy expenditure and body composition after weight loss following Roux-en-Y gastric bypass. Obes Surg 17: 612–620
Clements RH, Katasani VG, Palepu R, Leeth R, Leath TD, Roy TP, Vickers SM (2006) Incidence of vitamin deficiency after laparoscopic Roux-en-Y gastric bypass in a university hospital setting. Am Surg 72: 1196–1204
Folope V, Coeffier M, Dechelotte P (2007) Nutritional deficiency associated with bariatric surgery. Gastroenterol Clin Biol 31: 369–377
Hell E, Miller K (2000) Morbide Adipositas — Klinik und chirurgische Therapie. Ecomed, Landsberg, ISBN 3-609-20181-9
Rhode BM, Shustik C, Christou NV, MacLean L (1999) Iron absorption and therapy after gastric bypass. Obes Surg 9: 17–21
Rhode BM, Tamim H, Gilfix BM, Sampalis JS, Nohr C, Mac Lean LD (1995) Treatment of vitamin B12 deficiency after gastric surgery for severe obesity. Obes Surg 5: 154–158
Skroubis G, Sakellaropoulos G, Pouggouras K, Mead N, Nikiforidis G, Kalfarentzos F (2002) Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg 12: 551–558
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Saely, C.H. et al. (2010). Metabolismus. In: Ledochowski, M. (eds) Klinische Ernährungsmedizin. Springer, Vienna. https://doi.org/10.1007/978-3-211-88900-8_16
Download citation
DOI: https://doi.org/10.1007/978-3-211-88900-8_16
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-88899-5
Online ISBN: 978-3-211-88900-8
eBook Packages: Medicine (German Language)